Heidelberg‑based Exciva raised €51 million ($59 million) in a Series B to advance a candidate targeting agitation in Alzheimer’s disease into Phase 2 testing. Company statements indicate proceeds will fund the mid‑stage study and associated development activities. The financing is framed as a bridge to clinical proof of concept for a symptom‑focused neuropsychiatric indication that lacks approved pharmacologic options. The raise highlights continued investor appetite for CNS symptom‑management programs with clear path to mid‑stage data. Details on the molecule’s mechanism and trial design were not disclosed in the summary, but the funding positions Exciva to initiate and complete the planned Phase 2 readouts needed to attract partnering interest or later‑stage financing.